Cancer Supportive Care Drugs Market
Cancer Supportive Care Drugs Market Forecasts to 2030 - Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Other Cancer Types), Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel and By Geography
According to Stratistics MRC, the Global Cancer Supportive Care Drugs Market is accounted for $21.46 billion in 2023 and is expected to reach $26.57 billion by 2030 growing at a CAGR of 2.4% during the forecast period. Cancer supportive care drugs are medications designed to manage the symptoms and side effects of cancer treatment, aiming to improve patients' quality of life. These drugs target various issues such as pain, nausea, fatigue, and immune suppression caused by chemotherapy, radiation therapy, or other cancer treatments. They include analgesics, antiemetics, hematopoietic growth factors, and anti-inflammatory agents. These drugs also assist in maintaining treatment adherence by reducing discomfort and enhancing overall well-being.
According to the SEER Database of the U.S. National Cancer Institute, 2020, in the next twenty years, there will likely be 28.4 million new instances of cancer.
Market Dynamics:
Driver:
Rising prevalence of cancer globally
With an increasing number of individuals diagnosed with cancer, there is a higher demand for supportive care drugs to manage symptoms and side effects associated with cancer treatments. This increased demand stems from the necessity to alleviate pain, nausea, fatigue, and other treatment-related complications, enhancing patients' quality of life. Consequently, pharmaceutical companies are motivated to develop and innovate supportive care drugs, driving market expansion to meet the growing healthcare needs of cancer patients worldwide.
Restraint:
Side effects and toxicity
Side effects of cancer supportive care drugs can include nausea, vomiting, fatigue, anaemia, neuropathy, and immunosuppression. Additionally, some drugs may pose risks of toxicity to organs such as the liver or kidneys. These side effects and toxicities can lead to treatment interruptions, dose reductions, or discontinuation, affecting patient adherence and treatment outcomes. Moreover, concerns about adverse effects may deter healthcare providers from prescribing certain drugs, impacting market demand.
Opportunity:
Expansion of palliative care services
Palliative care integration underscores the importance of managing pain, nausea, and other side effects, prompting the development and adoption of supportive care drugs. Expansion of palliative care services increases the demand for medications that alleviate symptoms and improve quality of life for cancer patients. This expansion not only enhances patient well-being but also creates a conducive environment for pharmaceutical companies to innovate and introduce new therapies tailored to address the unique needs of individuals undergoing cancer treatment, thereby fueling market growth.
Threat:
Inadequate healthcare infrastructure
Insufficient facilities, trained personnel, and resources lead to delays in diagnosis, treatment initiation, and proper management of cancer-related symptoms. Moreover, poor infrastructure often results in disparities in healthcare delivery, disproportionately affecting underserved populations. Without adequate infrastructure to support comprehensive cancer care, the demand for supportive care drugs remains unmet, hindering market expansion and depriving patients of essential treatments to alleviate symptoms and improve quality of life.
Covid-19 Impact
The covid-19 pandemic has significantly impacted the cancer supportive care drugs market. Delays in cancer screenings, diagnosis, and treatment, alongside disruptions in healthcare services, have affected the demand for supportive care drugs. Additionally, supply chain disruptions and resource reallocation to address the pandemic have further strained market dynamics. Overall, the pandemic has underscored the importance of resilient healthcare systems and highlighted the need for innovative approaches to cancer care delivery.
The prostate cancer segment is expected to be the largest during the forecast period
The prostate cancer segment is estimated to have a lucrative growth. In the realm of cancer supportive care drugs, addressing the challenges of prostate cancer entails a multifaceted approach. Supportive care drugs for prostate cancer aim to mitigate treatment side effects and improve patients' quality of life. Additionally, drugs targeting prostate cancer-specific symptoms and complications, such as urinary issues or erectile dysfunction, may also play a crucial role. The development and availability of these drugs are pivotal in enhancing the holistic care and well-being of prostate cancer patients.
The intravenous drugs segment is expected to have the highest CAGR during the forecast period
The intravenous drugs segment is anticipated to witness the highest CAGR growth during the forecast period. Intravenous drugs play a pivotal role in cancer supportive care by delivering medications directly into the bloodstream, ensuring rapid and efficient absorption. These drugs are crucial for managing chemotherapy-induced side effects such as nausea, vomiting, anaemia, neutropenia, and pain. They offer targeted treatment, allowing for precise dosing and immediate relief, thereby enhancing the quality of life for cancer patients undergoing treatment.
Region with largest share:
Asia Pacific is projected to hold the largest market share during the forecast period. Increasing cancer prevalence, particularly in populous countries like China and India, drives demand for supportive care drugs to manage symptoms and side effects of cancer treatment. Additionally, improving healthcare infrastructure and rising awareness about cancer care contribute to market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with government initiatives to enhance cancer care services, further propel the growth of the cancer supportive care drugs market.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and strong emphasis on research and development contribute to this growth. Moreover, favourable reimbursement policies and increasing awareness among both patients and healthcare providers drive demand for supportive care drugs. With a focus on improving patient outcomes and quality of life, North America remains a key region for the development and commercialization of cancer supportive care drugs.
Key players in the market
Some of the key players profiled in the Cancer Supportive Care Drugs Market include Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis International AG, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, F. Hoffmann-La Roche Limited, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Daiichi Sankyo Company.
Key Developments:
In November 2023, AstraZeneca’s Truqap in combination with Faslodex has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations. Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.
In March 2022, Novartis received approval from the United States Food and Administration (FDA) for Pluvicto, developed for the treatment of adult patients with prostate cancer. The cancer supportive care drug by Novartis is specially designed for cancer patients that already have had other anti-cancer therapies.
Cancer Types Covered:
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancer Types
Supportive Care Types Covered:
• Chemotherapy-induced Nausea & Vomiting (CINV) Management
• Anaemia Management
• Neutropenia Management
• Bone Metastasis Management
• Pain Management
• Fatigue Management
• Other Supportive Care Types
Drug Types Covered:
• Anti-emetics
• Erythropoiesis-stimulating Agents (ESAs)
• Granulocyte Colony-stimulating Factors (G-CSFs)
• Bisphosphonates
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Other Drug Types
Mode of Administrations Covered:
• Oral Drugs
• Injectable Drugs
• Topical Drugs
• Intravenous Drugs
• Other Mode of Administrations
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Cancer Treatment Centers
• Other Distribution Channels
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cancer Supportive Care Drugs Market, By Cancer Type
5.1 Introduction
5.2 Breast Cancer
5.3 Lung Cancer
5.4 Prostate Cancer
5.5 Colorectal Cancer
5.6 Other Cancer Types
6 Global Cancer Supportive Care Drugs Market, By Supportive Care Type
6.1 Introduction
6.2 Chemotherapy-induced Nausea & Vomiting (CINV) Management
6.3 Anaemia Management
6.4 Neutropenia Management
6.5 Bone Metastasis Management
6.6 Pain Management
6.7 Fatigue Management
6.8 Other Supportive Care Types
7 Global Cancer Supportive Care Drugs Market, By Drug Type
7.1 Introduction
7.2 Anti-emetics
7.3 Erythropoiesis-stimulating Agents (ESAs)
7.4 Granulocyte Colony-stimulating Factors (G-CSFs)
7.5 Bisphosphonates
7.6 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
7.7 Corticosteroids
7.8 Other Drug Types
8 Global Cancer Supportive Care Drugs Market, By Mode of Administration
8.1 Introduction
8.2 Oral Drugs
8.3 Injectable Drugs
8.4 Topical Drugs
8.5 Intravenous Drugs
8.6 Other Mode of Administrations
9 Global Cancer Supportive Care Drugs Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
9.5 Cancer Treatment Centers
9.6 Other Distribution Channels
10 Global Cancer Supportive Care Drugs Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Amgen Inc.
12.2 Johnson & Johnson
12.3 Pfizer Inc.
12.4 Novartis International AG
12.5 Merck & Co. Inc.
12.6 Teva Pharmaceutical Industries Limited
12.7 F. Hoffmann-La Roche Limited
12.8 Bayer AG
12.9 Eli Lilly and Company
12.10 AstraZeneca PLC
12.11 Bristol Myers Squibb
12.12 GlaxoSmithKline PLC
12.13 Takeda Pharmaceutical Company Limited
12.14 AbbVie Inc.
12.15 Daiichi Sankyo Company
List of Tables
1 Global Cancer Supportive Care Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Type (2021-2030) ($MN)
3 Global Cancer Supportive Care Drugs Market Outlook, By Breast Cancer (2021-2030) ($MN)
4 Global Cancer Supportive Care Drugs Market Outlook, By Lung Cancer (2021-2030) ($MN)
5 Global Cancer Supportive Care Drugs Market Outlook, By Prostate Cancer (2021-2030) ($MN)
6 Global Cancer Supportive Care Drugs Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
7 Global Cancer Supportive Care Drugs Market Outlook, By Other Cancer Types (2021-2030) ($MN)
8 Global Cancer Supportive Care Drugs Market Outlook, By Supportive Care Type (2021-2030) ($MN)
9 Global Cancer Supportive Care Drugs Market Outlook, By Chemotherapy-induced Nausea & Vomiting (CINV) Management (2021-2030) ($MN)
10 Global Cancer Supportive Care Drugs Market Outlook, By Anaemia Management (2021-2030) ($MN)
11 Global Cancer Supportive Care Drugs Market Outlook, By Neutropenia Management (2021-2030) ($MN)
12 Global Cancer Supportive Care Drugs Market Outlook, By Bone Metastasis Management (2021-2030) ($MN)
13 Global Cancer Supportive Care Drugs Market Outlook, By Pain Management (2021-2030) ($MN)
14 Global Cancer Supportive Care Drugs Market Outlook, By Fatigue Management (2021-2030) ($MN)
15 Global Cancer Supportive Care Drugs Market Outlook, By Other Supportive Care Types (2021-2030) ($MN)
16 Global Cancer Supportive Care Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
17 Global Cancer Supportive Care Drugs Market Outlook, By Anti-emetics (2021-2030) ($MN)
18 Global Cancer Supportive Care Drugs Market Outlook, By Erythropoiesis-stimulating Agents (ESAs) (2021-2030) ($MN)
19 Global Cancer Supportive Care Drugs Market Outlook, By Granulocyte Colony-stimulating Factors (G-CSFs) (2021-2030) ($MN)
20 Global Cancer Supportive Care Drugs Market Outlook, By Bisphosphonates (2021-2030) ($MN)
21 Global Cancer Supportive Care Drugs Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
22 Global Cancer Supportive Care Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
23 Global Cancer Supportive Care Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
24 Global Cancer Supportive Care Drugs Market Outlook, By Mode of Administration (2021-2030) ($MN)
25 Global Cancer Supportive Care Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
26 Global Cancer Supportive Care Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
27 Global Cancer Supportive Care Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
28 Global Cancer Supportive Care Drugs Market Outlook, By Intravenous Drugs (2021-2030) ($MN)
29 Global Cancer Supportive Care Drugs Market Outlook, By Other Mode of Administrations (2021-2030) ($MN)
30 Global Cancer Supportive Care Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
31 Global Cancer Supportive Care Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
32 Global Cancer Supportive Care Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
33 Global Cancer Supportive Care Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
34 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
35 Global Cancer Supportive Care Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
